Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

FDA May Ask Circulatory Panel To Revisit AF Burden Definition, CryoCor Says

This article was originally published in The Gray Sheet

  • News

Executive Summary

The CryoCor cardiac cryoablation system will be the first FDA-approved device for treating paroxysmal (episodic) atrial fibrillation by ablating the pulmonary vein ostia, the source of about one-third of all AF, according to San Diego developer CryoCor

You may also be interested in...



CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring

CardioFocus expects its Light Ring catheter to be among the first devices to cure drug-resistant paroxysmal atrial fibrillation (AF) in patients not indicated for surgery

CardioFocus Illuminates Underserved “AF-Alone” Market With Light Ring

CardioFocus expects its Light Ring catheter to be among the first devices to cure drug-resistant paroxysmal atrial fibrillation (AF) in patients not indicated for surgery

ADOPT-A Trial Kicks SJM Into Overdrive In Race For AF Suppression Pacing

St. Jude said it expects to earn the first PMA approval of a pacing algorithm for the treatment of atrial fibrillation (AF) based on its Atrial Dynamic Overdrive Pacing Trial-A (ADOPT-A).

Table

View full table

Tags:
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

MT016538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By